MSB trading, page-2130

That may be the case (although that analogy to thalidomide was considering a commonly used treatment, not an experimental one). I think we can assume at the very least the treatment was safe. If it wasn't, they would have to consider cancelling other trials.

I still think that on balance, based on the type of presentation it is and everything else we know, it's probably very good results. The question for the market will probably not be "does it work" the questions are likely to be "how well does it work" and "how often does it work".

I reckon the market has already priced in positive results for the LVAD trial. That's why the the SP is resting well above $2 instead of dropping back to $1.90 or so. What will influence the SP most will be the how well and how often answers.